Nanobiotix: First Successes in the Fight Against Treatment-Resistant Cancer Thanks to Nanotechnology
Reading Time: 3 minutes
The French company shows exciting parallels in its stock performance to the medical technology specialist ClearPoint Neuro presented yesterday. Nanobiotix has also been in a downward trend in recent years. Except for a revenue of €30 million in 2023, it has generated no significant income despite the great potential in nanotechnology. Multiple promising study results since September 17, 2025, are now providing strong new impulses. Currently, the stock is at its highest level since September 2017. The all-time high from January 2015 is only 30%...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
